$0.41
(Market cap
$260 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
7.4
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.3 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
1.1
-
Debt to Equity
0.2
-
Book Value
$--
-
EPS
$--
-
Face value
--
-
Shares outstanding
66,072,594
6 Years Aggregate
CFO
$-181.43 Mln
EBITDA
$-226.93 Mln
Net Profit
$-220.54 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Adagene (ADAG)
| 108.5 | 12.6 | 0.8 | 105.2 | 45.5 | -22.4 | -- |
|
BSE Sensex*
| -9.3 | 2.0 | 0.1 | -5.7 | 6.6 | 8.0 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Adagene (ADAG)
| -5.0 | 3.0 | 45.7 | -83.6 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Adagene (ADAG)
|
3.9 | 260.3 | 7.7 | -17.6 | -49,331.1 | -41 | -- | 7.4 |
| 278.1 | 37,128.5 | 4,286.9 | 577.2 | 20.3 | 88.2 | 69.9 | 34.5 | |
| 81.8 | 11,524.9 | 622.0 | -300.9 | -25.7 | -61.1 | -- | 18.7 | |
| 51.9 | 13,047.8 | 2,375.5 | 833.4 | 41.5 | 40.7 | 17.2 | 6.7 | |
| 167.8 | 28,000.8 | 16,632.0 | 1,385.0 | 14.1 | 22.3 | 20.9 | 4.5 | |
| 505.8 | 11,660.4 | 1,132.5 | -309.4 | -25.0 | -52.9 | -- | 21.4 | |
| 460.2 | 13,143.2 | 2,678.3 | 460.4 | 21.3 | 103.2 | 29 | 22.0 | |
| 609.9 | 63,945.5 | 14,919.6 | 4,423.4 | 34.9 | 14.2 | 14.9 | 2.0 | |
| 536.6 | 22,776.5 | 3,169.8 | 1,287.4 | 51.3 | 20.6 | 19.8 | 3.9 | |
| 451.6 | 114,626.1 | 12,255.1 | 4,338.3 | 32.0 | 23.7 | 26.8 | 5.9 |
Shareholding Pattern
View DetailsAbout Adagene (ADAG)
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human... anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. Adagene Inc. was incorporated in 2011 and is headquartered in Suzhou, China. Read more
-
Co- Founder, Chairman, CEO and President of R&D
Dr. Peter P. Luo Ph.D.
-
Co- Founder, Chairman, CEO and President of R&D
Dr. Peter P. Luo Ph.D.
-
Headquarters
Suzhou
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Adagene (ADAG)
What is the current share price of Adagene Inc (ADAG) Today?
The share price of Adagene Inc (ADAG) is $3.94 (NASDAQ) as of 18-Jun-2026 19:41 EDT. Adagene Inc (ADAG) has given a return of 45.47% in the last 3 years.
What is the current PB & PE ratio of Adagene Inc (ADAG)?
Since, TTM earnings of Adagene Inc (ADAG) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
--
|
--
|
|
2024
|
--
|
--
|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
What is the 52 Week High and Low of Adagene Inc (ADAG)?
The 52-week high and low of Adagene Inc (ADAG) are Rs 4.75 and Rs 1.30 as of 21-Jun-2026.
What is the market cap of Adagene Inc (ADAG)?
Adagene Inc (ADAG) has a market capitalisation of $ 260 Mln as on 18-Jun-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Adagene Inc (ADAG)?
Before investing in Adagene Inc (ADAG), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.